Cadence Molecular Sciences Joins ASAP Consortium to Combat Future Pandemics

Cadence Molecular Sciences (OpenEye), a subsidiary of Cadence Design Systems, is joining forces with the AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium to accelerate the development of effective antivirals to combat future pandemics.

Cadence Molecular Sciences will contribute its leading molecular design software, OpenEye, to power the ASAP platform. This software utilizes artificial intelligence and computational chemistry to streamline the process of identifying and optimizing antiviral drug candidates.

"We are thrilled to partner with the ASAP Consortium in this critical effort," said Dr. John Chodera, lab head at the Memorial Sloan Kettering Cancer Center "OpenEye will assist in accelerating the development of life-saving treatments to prepare for pandemics."

The ASAP Consortium, formed in the wake of the COVID-19 pandemic, is a global initiative that brings together researchers from academia, industry, and government leveraging open-science principles and advanced computational tools. The consortium aims to develop a rapid response system for identifying and developing effective antivirals against emerging threats.

This collaboration represents a significant milestone in the fight against future pandemics. By combining expertise in molecular design, artificial intelligence, and open-science collaboration, the ASAP consortium has the potential to make a lasting impact on global health.